All terms in NCIT
| Label | Id | Description |
|---|---|---|
| Dezapelisib | NCIT_C107686 | [An orally bioavailable, selective inhibitor of the delta isoform of the 110 kDa catalytic subunit of class I phosphoinositide-3 kinases (PI3K) with potential antineoplastic activity. Dezapelisib specifically inhibits PI3Kdelta, which prevents both the production of the second messenger phosphatidylinositol-3,4,5-trisphosphate (PIP3) and the activation of the PI3K/AKT kinase signaling pathway. This decreases proliferation and induces cell death in PI3K-overexpressing tumor cells. Unlike other isoforms of PI3K, PI3Kdelta is often overexpressed in tumor cells, especially those of hematologic origin, and plays a crucial role in tumor cell regulation and survival. The targeted inhibition of PI3Kdelta allows for PI3K signaling in normal, non-neoplastic cells.] |
| Unknown Primary Tumor pNX TNM Finding v8 | NCIT_C132666 | [Unknown primary tumor in which the regional lymph nodes cannot be assessed. (from AJCC 8th Ed.)] |
| Autauga County, AL | NCIT_C107688 | |
| Unknown Primary Tumor pN0 TNM Finding v8 | NCIT_C132667 | [Unknown primary tumor in which no regional lymph node metastases are detected. (from AJCC 8th Ed.)] |
| Baldwin County, AL | NCIT_C107689 | |
| Doxycycline Hydrochloride | NCIT_C29010 | [The hydrochloride salt form of doxycycline exhibiting antimicrobial activity. Doxycycline blocks binding of aminoacyl-tRNA to the mRNA-ribosome complex, thereby inhibiting protein synthesis. In addition, this agent has exhibited inhibition of collagenase activity. (NCI)] |
| Unknown Primary Tumor pN1 TNM Finding v8 | NCIT_C132668 | [Unknown primary tumor with metastasis in a single ipsilateral lymph node, 3 cm or smaller in greatest dimension and ENE (extranodal extension)(-). (from AJCC 8th Ed.)] |
| Doxycycline Monohydrate | NCIT_C29011 | [The monohydrate form of doxycycline exhibiting antimicrobial activity. Doxycycline blocks binding of aminoacyl-tRNA to the mRNA-ribosome complex, thereby inhibiting protein synthesis. In addition, this agent has exhibited inhibition of collagenase activity. (NCI)] |
| Dosage Form by Physical Form | NCIT_C87836 | |
| Chlorpheniramine/Methscopolamine/Phenylephrine Tablet Formulation | NCIT_C29013 | [A commercial combination preparation, by Biovail Pharmaceuticals, containing chlorpheniramine maleate, phenylephrine hydrochloride and methscopolamine nitrate used to relieve symptoms of cold and flu. Chlorpheniramine maleate, an antihistamine, blocks the effects of histamine, thereby preventing symptoms such as sneezing and itchy, watery eyes, runny nose and itchy throat. Phenylephrine hydrochloride, a sympathomimetic agent, acts as a decongestant by inducing blood vessels constriction mediated via alpha-adrenergic receptors, thereby reducing blood flow and decreasing swelling which prevents nasal and sinus congestion. Methscopolamine nitrate, an anticholinergic agent, may reduce fluid secretions and provides a drying effect in nose, eyes and chest.] |
| Nasal Cavity and Paranasal Sinus Squamous Cell Carcinoma | NCIT_C68611 | [A rare, keratinizing or non-keratinizing squamous cell carcinoma arising from the mucosal epithelium of the nasal cavity or the paranasal sinuses. It affects most often the maxillary sinus. Less frequently, it arises from the nasal cavity, ethmoid sinus, sphenoid sinus, and frontal sinus. Symptoms include nasal fullness, epistaxis, rhinorhea, pain, and paresthesia. Patients with nasal squamous cell carcinoma usually present earlier than patients with maxillary sinus carcinoma and have a better prognosis compared to the latter group.] |
| Nasal Cavity and Paranasal Sinus Carcinoma | NCIT_C54293 | [A carcinoma arising from the nasal cavity or paranasal sinuses.] |
| Microscope | NCIT_C20677 | [A microscope is an optical instrument that uses a combination of lenses to produce magnified images of very small objects] |
| Duratec | NCIT_C29014 | |
| Active Comparator Drug | NCIT_C68612 | [A therapeutically active agent that is intended to provide baseline measurements for the experimental protocol of a clinical trial.] |
| Robot | NCIT_C20678 | [A mechanical device that sometimes resembles a living animal and is capable of performing a variety of often complex human tasks on command or by being programmed in advance.] |
| Dyclonine | NCIT_C29015 | [An unclassified compound with local anesthetic effect. Dyclonine reversibly binds to activated sodium channels on the neuronal membrane, thereby decreasing the neuronal membrane's permeability to sodium ions, leading to an increased threshold for excitation. This reversibly stabilizes the membrane and inhibits depolarization, leading to the failure of a propagated action potential and subsequent conduction blockade. This results in a transient and reversible loss of sensation in a localized area of the body.] |
| Post-Study Adverse Event | NCIT_C68613 | [An adverse event that occurred after the patient had completed a clinical study (including any protocol-required post-treatment follow-up).] |
| Adverse Event by Type | NCIT_C154678 | |
| Protein Phosphorylation Process | NCIT_C18496 | [Protein phosphorylation is one of various post-translational protein modifications that regulates protein function and enzymatic activity. The major phosphoryl acceptors in proteins are serine, threonine, and tyrosine.] |